NASAL VACCINES MARKET ANALYSIS

The global nasal vaccines market size was valued at US$ 416.8 million in 2023 and is expected to reach US$ 742.6 million by 2030, grow at a Compound Annual Growth Rate (CAGR) of 8.6% from 2023 to 2030.

The nasal vaccines market refers to the segment of the pharmaceutical industry that focuses on the development, production, and distribution of vaccines administered through the nasal route. Nasal vaccines are a type of immunization that is delivered via intranasal administration, typically in the form of a nasal spray. These vaccines are designed to stimulate an immune response in the mucosal surfaces of the respiratory tract, providing protection against respiratory infections caused by specific pathogens such as influenza, COVID-19, and others.

The nasal vaccines market has witnessed significant growth in recent years, driven by factors such as the increasing demand for needle-free vaccine delivery methods, the potential for enhanced mucosal immunity, ease of administration, and potential for improved patient compliance, particularly in the pediatric population. Nasal vaccines are being developed for a range of infectious diseases, and ongoing research aims to expand their applications.

Nasal Vaccines Market Regional Insights

• North America: North America is the leading market for nasal vaccines, accounted for a market share of over 35% in 2022. North America, notably the U.S., has a large presence in the nasal vaccinations industry The region has a well-developed healthcare infrastructure, a robust vaccine industry, and advanced research capabilities. The demand for nasal vaccines is driven by factors such as the need for effective respiratory disease prevention, the presence of major pharmaceutical companies, and high healthcare expenditure.
• Europe: Europe is also an important market for nasal vaccines. The region has a strong focus on immunization programs and preventive healthcare, leading to a favorable environment for the adoption of nasal vaccines. Countries, such as the U.K., Germany, and France, have made advancements in nasal vaccine research and development, contributing to market growth, and Europe is the second largest market for nasal vaccines, accounted for a market share of over 25% in 2022.
• Asia Pacific: Asia Pacific is the fastest growing market for nasal vaccines, accounted for a market share of over 20% in 2022 and The Asia Pacific region represents a significant opportunity for the nasal vaccines market. The rising population, increasing healthcare investments, and growing awareness of preventive healthcare contribute to market growth. Countries like China and India have witnessed a surge in vaccine production and research activities, supporting the development of nasal vaccines.

Figure 1. Global Nasal Vaccines Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Analyst’s Views on Global Nasal Vaccines Market:

• The rising number of patients suffering from COVID-19 is expected to drive the market growth over the forecast period as nasal vaccines are used in the treatment of the disease. For instance, according to the World health Organization (WHO), there have been 771,549,718 confirmed cases of COVID-19 as of October 25, 2023. Thus, the increased prevalence of COVID-19 provides an opportunity for numerous manufacturers to offer various nasal vaccinations to treat the disease.

Nasal Vaccines Market Drivers:

• Needle-free vaccine delivery: Nasal vaccines offer a needle-free vaccine delivery method, which is especially attractive for individuals with a fear of needles, pediatric populations, and those who prefer a painless and convenient vaccination experience. The needle-free approach drives the demand for nasal vaccines and improves patient compliance. Increase adoption of needle-free vaccines, such as nasal vaccines, will drive the market growth over forecast period. For instance, on October 26, 2023, Mylab Discovery Solutions Pvt. Ltd., a biopharmaceutical and diagnostic company, and Serum Institute of India, pvt. Ltd., a biopharmaceutical company, announced the launch of nasal influenza vaccine Nasovac S4 in India. It is India’s first needle-free nasal influenza vaccine.
• Enhanced mucosal immunity: Nasal vaccines target the mucosal surfaces of the respiratory tract, stimulating local immune responses. This mucosal immunity can provide an additional line of defense against respiratory pathogens by preventing their entry and replication at the site of infection. The potential for enhanced mucosal immunity drives the development and adoption of nasal vaccines.
• Potential for improved vaccine efficacy: The nasal route of vaccine administration has shown the potential to enhance vaccine efficacy for certain respiratory pathogens. By directly targeting the respiratory mucosa, nasal vaccines can trigger a robust immune response at the site of infection, leading to improved protection against respiratory diseases.
• Rapid onset of immune response: Nasal vaccines can induce a more rapid immune response compared to traditional injectable vaccines. The nasal mucosa contains a high density of immune cells, enabling a quicker activation of immune mechanisms upon administration of nasal vaccines. This rapid onset of immune response is particularly beneficial in outbreak situations or for rapid protection against infectious diseases.

Nasal Vaccines Market Opportunities:

• Rising prevalence of diseases such as influenza: The increasing prevalence of diseases, such as influenza, is expected to offer lucrative growth opportunities for the growth of the global nasal vaccines market over the forecast period as nasal vaccines are used to treat influenza. For instance, according to data published by the WHO, on October 3, 2023, annually, there are around one billion incidents of seasonal influenza, with 3-5 million cases of severe disease.
• Expanded vaccine coverage: There is an opportunity to expand the coverage of existing vaccines through nasal delivery. Many traditional injectable vaccines could potentially be reformulated as nasal vaccines, offering a needle-free and potentially more effective alternative. Exploring the conversion of injectable vaccines into nasal vaccines can broaden the range of preventable diseases and increase market penetration.
• Pediatric vaccination: Nasal vaccines offer an attractive option for pediatric vaccination. Expanding the range of vaccines available in nasal form, especially for diseases that predominantly affect children, can improve vaccination rates and compliance in this population

Nasal Vaccines Market Trends:

• Advancements in vaccine delivery technologies: The nasal vaccines market has witnessed advancements in vaccine delivery technologies. This includes the development of improved nasal spray devices, innovative formulations, and delivery systems that enhance vaccine stability, mucosal targeting, and immune response. Market players are focused on the partnerships for the development of nasal spray vaccines. For instance, In March 2021, Altimmune, a clinical-stage biopharmaceutical company, and Summit Biosciences, a global player in nasal spray pharmaceuticals, announced a partnership to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate.
• Increased focus on respiratory pathogens: There is a heightened focus on developing nasal vaccines for respiratory pathogens, especially in light of the COVID-19 pandemic. The need for effective prevention and control of respiratory infections has accelerated research and development efforts in this area.
• Development of needle-free pediatric vaccines: Nasal vaccines are gaining traction as a needle-free alternative for pediatric vaccinations. The ease of administration, reduced pain, and potential for improved compliance make them attractive for immunizing children against respiratory diseases
• Expansion of immunization programs: Nasal vaccines are being included in national immunization programs in various countries. Governments and public health agencies are recognizing the benefits of nasal vaccines, leading to their inclusion for the prevention of respiratory infections such as influenza.

Nasal Vaccines Market Restraints:

• Regulatory hurdles: Nasal vaccines face specific regulatory challenges, including the need to demonstrate safety, efficacy, and quality standards for intranasal administration. Obtaining regulatory approvals can be time-consuming and expensive, potentially delaying market entry or hindering product development.
• Limited vaccine targets: Nasal vaccines have primarily been developed for respiratory pathogens, and their application is limited to specific diseases. Developing Nasal Vaccines for a broader range of infectious diseases, such as non-respiratory infections, may pose technical and immunological challenges.
• Vaccine Stability and Formulation: Nasal vaccines require stable formulations to ensure vaccine integrity and efficacy. Maintaining stability during storage, transportation, and administration can be challenging, particularly for live attenuated vaccines or those containing complex antigens.

Figure 2. Global Nasal Vaccines Market Share (%), by Vaccine Type, 2023

To learn more about this report, request a free sample copy

Recent Developments

Partnerships & Collaborations

• In October 2022, Coalition for Epidemic Preparedness Innovations partnered with Intravacc, a contract development and manufacturing organization for the development of an intranasal, broadly protective Betacoronavirus vaccine
• In September 2020, Pfizer, a global biopharmaceutical company in collaboration with BioNTech SE, a biopharmaceutical company announced preliminary preclinical evidence from its BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease, in mouse and non-human primate models. Immunization with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection in a non-human primate preclinical investigation via both intranasal (nose) and intratracheal (lung) routes.

Product Approvals & Launches

• In January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company launched iNCOVACC, a nasal vaccine used in treatment of COVID-19 in India.
• In September 2022, Bharat Biotech, an India-based global biopharmaceutical company, received approval from Central Drugs Standard Control Organisation (CDSCO) for iNCOVACC (BBV154), an intranasal vaccine under Restricted Use in Emergency Situation for ages 18 and above in India for the treatment of COVID-19

Top Companies in the Nasal Vaccines Market

• AstraZeneca
• GlaxoSmithKline plc
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• SINOVAC
• Bharat Biotech
•  Altimmune
• FluGen Inc.
• Vaxart
• Intravacc
• Gamma Vaccines Pty Ltd.
•  BioNTech SE

*Definition: Nasal vaccines, also known as intranasal vaccines, are a type of immunization administered through the nasal route via a nasal spray or dropper. These vaccines stimulate an immune response in the mucosal surfaces of the respiratory tract, targeting the Mucosa-associated Lymphoid Tissue (MALT) and inducing both local and systemic immune protection. Nasal vaccines offer the advantage of needle-free administration, potentially enhancing patient compliance, and have the potential to provide mucosal immunity against respiratory infections caused by specific pathogens such as influenza, COVID-19, and other respiratory viruses.